SEATTLE, July 28, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its second quarter 2014 financial results on Monday, August 4, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT ( 1:30 p.m. PDT). Access to the event can be obtained as follows:
Monday, August 4 1:30 p.m. PDT/ 4:30 p.m. EDT/ 10:30 p.m. CEST 1-888-461- 2024 (domestic) +1 719-325-2464 (international)
To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.ctibiopharma.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-888-203-1112 (domestic) or +1 719-457-0820 (international). The access code for the replay is #1937280. The telephone replay will be available until Monday, August 11, 2014.
About CTI BioPharmaCTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI's lead product candidate that is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com. Contacts: Monique Greer +1 206-272-4343 email@example.com Ed Bell +1 206-282-7100 firstname.lastname@example.org In Europe: CTI Life Sciences Limited, Milan Branch Laura Villa +39 02 94751572 email@example.com SOURCE CTI BioPharma Corp.